

1 **A novel fusion method of 3D MRI and test results through deep learning for the** 2 **early detection of Alzheimer’s disease**

3

4 Arman Atalar^{1,2}, Nihat Adar^{3,4}, Savaş Okyay⁴

5

6

7 ¹Department of Computer Programming, Eskişehir Osmangazi University, Vacation School, Eskişehir, Türkiye

8 ²Department of Computer Engineering, Yıldız Technical University, İstanbul, Türkiye

9 ³Canadian Institute of Technology, Tirana, Albania

10 ⁴Department of Computer Engineering, Eskişehir Osmangazi University, Faculty of Engineering and Architecture,

11 Eskişehir, Türkiye

12

13 Corresponding Author:

14 Arman Atalar^{1,2}

15 Eskişehir Osmangazi University, Eskişehir, 26040, Türkiye

16 Email address: atar@ogu.edu.tr

17

18 **Abstract**

19 Alzheimer’s disease (AD) is a prevalent form of dementia that impacts brain cells. Although its

20 likelihood increases with age, there is no transitional period between its stages. In order to enhance

21 diagnostic precision, physicians rely on clinical judgments derived from interpreting health data,

22 considering demographics, clinical history, and laboratory results to detect AD at an early stage.

23 While patient cognitive tests and demographic information are primarily presented in text, brain

24 scan images are presented in graphic formats. Researchers typically use different classifiers for
25 each data format and then merge the classifier outcomes to maximize classification accuracy and
26 utilize all patient-related data for the final decision. However, this approach leads to low
27 performance, diminishing predictive abilities and model effectiveness.

28 We propose an innovative approach that combines diverse textual health records (HR) with three-
29 dimensional structural magnetic resonance imaging (3D sMRI) to achieve a similar objective in
30 computer-aided diagnosis, utilizing a novel deep learning technique. Health records, encompassing
31 demographic features like age, gender, apolipoprotein gene, and mini-mental state examination
32 score, are fused with 3D sMRI, enabling a graphic-based deep learning strategy for early AD
33 detection. The fusion of data is accomplished by representing textual information as graphic pipes
34 and integrating them into 3D sMRI, a method referred to as the “pipe-laying” method.

35 Experimental results from over 4000 sMRI scans of 780 patients in the AD Neuroimaging Initiative
36 (ADNI) dataset demonstrate that the pipe-laying method enhances recognition accuracy rates for
37 Early and Late Mild Cognitive Impairment (MCI) patients, accurately classifying all AD patients.
38 In a 4-class AD diagnosis scenario, accuracy improved from 86.87% when only 3D images were
39 used to 90.00% when 3D sMRI and patient health records were included. Thus, the positive impact
40 of combining 3D sMRI with HR on 4-class AD diagnosis was established.

41

42

43 **Key Word:** 3D CNN, Alzheimer, MRI, Deep Learning, Data Fusion.

44

45

46 **Introduction**

47 Alzheimer's disease (AD) is the most common form of dementia, leading to cognitive confusion.
48 The disease advances gradually, resulting in the deterioration of brain cells, impacting memory and
49 cognitive functions, and disrupting daily activities. According to data from the World Health
50 Organization, around 55 million individuals suffer from dementia, with AD constituting 60–70%
51 of these instances. As the elderly population continues to grow, the number of diagnosed patients
52 is projected to escalate to 97 million in the foreseeable future. Developed nations currently observe
53 a 13% prevalence of AD among people aged over 65, and this rate is on the rise (1). Since AD is a
54 type of dementia with a surreptitious onset in the form of episodic memory loss, its early-stage
55 diagnosis poses challenges. Although no definitive cure for AD exists, treatment methods have
56 shown the potential to slow down or even halt disease progression (2). Given that cognitive
57 impairments become noticeable in later stages, rendering effective treatment challenging, early
58 diagnosis becomes crucial to apply interventions that can decelerate or even stop the disease's
59 advancement.

60 Mild cognitive impairment (MCI) is the stage between the anticipated age-related decline in
61 memory and cognitive function and the more profound deterioration characteristic of dementia.
62 MCI serves as the intermediary stage and might escalate into dementia as cognitive decline
63 becomes more severe. However, it remains unclear whether the symptoms observed at this stage
64 lead to AD. Investigations centered on sMRI images of patients in this stage have revealed
65 various physical changes in the brain structure. Noteworthy transformations encompass the
66 shrinkage of the hippocampus, pivotal for learning and memory, increased ventricular space, and
67 decreased glucose utilization in certain brain regions. Late and early stages of MCI were
68 established to enhance the comprehension of how MCI impacts Alzheimer's disease. Early Mild

69 Cognitive Impairment (EMCI) exhibits distinct traits like amyloid buildup, disruptions in
70 functional networks, and variations in brain volume. The ADNI findings indicate that individuals
71 with Late Mild Cognitive Impairment (LMCI) and EMCI face a greater risk of developing
72 dementia linked to Alzheimer's disease. Contrasted with LMCI patients, those with EMCI
73 demonstrate more heterogeneous characteristics and are more prone to show negative indicators
74 of AD pathology. At the EMCI stage, baseline cognitive function and APOE4 positive status
75 associated with poor cognitive and functional outcomes. In the LMCI phase, the risk of AD
76 escalates with episodic memory impairment (3).

77 Various learning methods have been developed in this area because of the importance of the early
78 and accurate diagnosis of AD. In addition to imaging modalities, several other factors may be
79 linked to the early diagnosis of AD (2,4). Age, gender, education level, speech pattern, retinal
80 abnormalities, postural kinematic analysis, cerebrospinal biomarkers, neuropsychological
81 measures, and the values of certain genes are essential factors for disease identification (5). In
82 addition, different cognitive and reliable clinical test scores (6), such as the mini-mental state
83 examination, Montreal cognitive assessment, clinical dementia staging score, rey auditory verbal
84 learning test, everyday cognition test, Alzheimer's disease rating scale, and logical memory test,
85 are required to diagnose AD. After the neurological examination, blood tests, and mental tests,
86 brain imaging should be performed; and in some cases, electroencephalography (EEG), single-
87 photon emission computed tomography (SPECT) lumbar puncture, and psychiatric consultation
88 may be required (2). Using this information together with learning methods will make diagnosis
89 faster and more precise (4).

90 The majority of deep learning studies have employed neuroimaging techniques, including
91 magnetic resonance imaging (MRI) and positron emission tomography (PET). However, studies

92 utilizing alternative diagnostic data are scarce, and the majority of proposed methods have been
93 designed for use with 2D images. Textual and numerical measurement data, aside from images,
94 are integrated into deep learning approaches for diseases that require early diagnosis. The
95 incorporation of demographic, genetic, and cognitive score data into the diagnostic process
96 contributes to a more precise identification of diseases (5,7).

97 The diagnostic process for cognitive diseases entails the evaluation of a diverse set of data.
98 Simultaneous and integrated analyses of these data are crucial for early diagnosis. Machine
99 learning- and deep learning-based applications have incorporated data fusion methods to achieve
100 this objective (8). Data fusion involves extracting relevant information from a combination of
101 diverse data originating from various sources. This approach amalgamates multiple data sources to
102 facilitate comprehensive analysis. Data fusion studies involve merging data of the same type into
103 different formats and integrating distinct data types into different formats.

104 The data fusion methods suggested in the literature for the diagnosis of AD and MCI stages are
105 primarily focused on combining different images, such as MRI and PET (9). Analyzing contextual
106 data such as age, gender, education level, genetics, and cognitive test scores also holds significant
107 importance in the early disease diagnosis. Simultaneously assessing this data alongside images can
108 empower healthcare professionals to achieve early diagnoses.

109 This study aimed to create a decision support system for physicians, facilitating the differentiation
110 between AD and MCI stages through a simultaneous assessment of images and cognitive test
111 results. To achieve this, textual test results were transformed into 3D pipe image representations
112 and then fused with 3D structural magnetic resonance imaging (3D sMRI) for each patient. This
113 combined approach was named "3D sMRI with Health Records" (3DMRIwHR) for 3D images and
114 "2D sMRI with Health Records" (2DMRIwHR) for 2D images. Given the crucial significance of

115 early AD diagnosis, the proposed 3D convolutional neural networks (CNN) model was employed
116 to classify cognitively normal, early mild cognitive impairment, late mild cognitive impairment,
117 and AD stages in a multi-class fashion.

118

119 **Related work**

120 For the early diagnosis of AD, different methods, such as data diversification or model
121 development, are preferred for the multi-classification of its stages. Demographic information,
122 cognitive scores, genetic and neuroimaging data are commonly utilized in data diversification
123 studies. These data are evaluated either as individual features or integrated with the image data.

124 In a study published in 2018 that focused on separate evaluations of various data, it was observed
125 that the addition of the Mini-Mental State Examination (MMSE) score to MRI improved accuracy
126 in the classification of healthy controls, MCI, and AD groups using different machine learning
127 methods (10). Another study conducted in the same year combined MRI, positron emission
128 tomography (PET), Rey Auditory Verbal Learning Test (RAVLT), Montreal Cognitive
129 Assessment (MoCA), and Electrocochleography Testing (ECogT) standard neuropsychological
130 test scores to classify stages such as AD, EMCI, LMCI, and CN (11).

131 Data fusion has found application in various neuroimaging studies, with some combining diverse
132 image types while only a minority integrates demographic information with images. An example
133 involves the combination of MRI and PET using a zero-masking strategy, aiming to extract
134 complementary information from distinct data modalities (12). Additionally, Punjabi et al. (13)
135 demonstrated the fusion of MRI and amyloid PET, two widely used imaging modalities.
136 Preprocessing steps for the scans encompassed MRI bias field signal correction, affine recording,

137 and skull stripping. Initially, the methods were individually compared through the utilization of a
138 3D CNN. In the fusion approach, both imaging datasets underwent parallel processing in separate
139 branches, with features combined in the latter portion of the network through fully connected (FC)
140 layers.

141 In 2021, a method based on embedded feature selection and fusion using multi-modal
142 neuroimaging was proposed for AD diagnosis. By combining MRI, PET, and Cerebrospinal Fluid
143 (CSF) Factor biomarkers, promising outcomes were obtained for the classification of Healthy
144 Control, MCI, and AD (14). It has been suggested that the performance of the method for
145 multiple classifications of AD can be improved using multi-modal data. In this regard, various
146 modalities have been developed that combine MRI, PET, cerebrospinal fluid (CSF) biomarkers,
147 and genetic features. It has been observed that more effective results were achieved regarding the
148 multi-modal data scored with the linear discriminant analysis method (15).

149 In addition to multi-class studies, another study was conducted wherein different types of data were
150 integrated into the image, aiming to ascertain the transition from the MCI stage to AD. Through
151 the fusion of different data formats, Pelka et al. (16) employed a long short-term memory-based
152 recurrent neural network (RNN) model for image classification. This data fusion study implies that
153 superior outcomes can be achieved by integrating socio-demographic and medical data for disease
154 diagnosis. Pelka et al. introduced a branding approach wherein socio-demographic and genetic data
155 were encoded using markers on 2D MRI to attain a more advanced image representation and reduce
156 computational load. By employing the ADNI Phase I and Heinz Nixdorf Recall study databases,
157 the study generated five distinct markers denoting age, gender, education, marital status, and ApoE
158 $\epsilon 4$ gene values. The outcomes of the study, wherein branded and unbranded images from each
159 marker group underwent separate classification processes, underscored the general impact of

160 branded data on specificity, F1-score, and accuracy performance metrics for both the Heinz
161 Nixdorf Recall and ADNI Phase I databases.

162 Payan and Montana (17) proposed a two-step approach for feature extraction in a 3D CNN for
163 the classification of sMRI scans. They built a 3D CNN in which the convolutional layers were
164 pretrained using a sparse autoencoder, and directly used 3D sMRI as input data. However,
165 pretraining with the autoencoder was not fine-tuned; therefore, it was suggested that the
166 performance would have been improved by fine-tuning. The model achieved higher accuracy than
167 those of previous studies for multiple classifications. Similarly, a deeply supervised and adaptable
168 3D CNN (DSA-3D CNN) built on a 3D convolutional autoencoder (3D-CAE) was proposed to
169 capture variations in anatomical sMRI brain scans based on a previous study (18). As a threshold,
170 the 3D-CAE was pretrained using the CAD-Dementia dataset. The proposed model can learn
171 general and transferable features in different regions. The Hierarchical Attention-based Deep
172 Neural Network (HadNet) architecture was suggested for the classification of MRI images that
173 were normalized and skull-stripped (19).

174 It was concluded that this architecture achieved superior results in terms of sensitivity and
175 specificity. In another study, demographic information and clinical brain activity test scores were
176 marked on MRI images as landmarks for multi-classification. The preprocessed images and
177 landmarks were trained in the CNN model as two separate inputs. During training, the positions of
178 the landmarks were controlled, and the training of landmarks and images was conducted separately.
179 Joint learning was implemented during training. The main deficiency is that landmark detection
180 and landmark-based classification processes are independent (7). The brain images with the
181 landmark skull in the study included colored data on disease classification. Thus, landmarks should
182 be learned independently from CNN in unsupervised learning. In a previous study in which binary

183 and multi-classifications were made, four classes were used: AD, EMCI, LMCI, and NC (20). In
184 this study, 75 samples from each class label were used in the experiments.

185 It has been revealed that CNN models outperform machine learning methods in the domain of
186 medical image classification. Due to their revolutionary capabilities in capturing multi-region
187 features, CNN are widely used in the medical field to identify different types of diseases using
188 different medical imaging as input data (21). While a majority of data is in 2D format, like chest
189 X-rays or bone X-rays, and is well-suited for 2D CNNs. Advanced medical imaging (3D) produced
190 by sophisticated equipment can be exceptionally well-identified through the utilization of 3D
191 CNNs. Unlike 2D CNNs, 3D CNNs incorporate cross-layer contexts that are not easily discernible
192 through visual inspection. A pivotal distinction between 2D and 3D CNNs lies in the fact that 3D
193 CNNs can retain the spatial information inherent in images. Volumetric CNNs employ 3D filters
194 and generate a 3D volume output by processing the input through a sequence of convolutional
195 layers, including activation, pooling, dropout, and FC layers. Consequently, volumetric CNNs
196 function on the voxels of 3D images while preserving their spatial attributes.

197 Some studies have analyzed health records in conjunction with 3D image data, and the
198 methodologies they propose involve distinct stages, such as independent feature extraction prior to
199 classification. The autonomy of these stages leads to increased computational complexity and time
200 requirements. Consequently, to address the challenges associated with this approach and achieve
201 early disease diagnosis, this study introduces a method that fuses and simultaneously analyzes
202 textual clinical data and neuroimaging. Moreover, through classification using a deep learning
203 model, this method aims to discern the disease-induced patterns within the brain and identify
204 various stages of MCI and AD. In alignment with this objective, the study also investigates the
205 influence of health records on early diagnosis, assesses the effectiveness of CNNs in analyzing

206 sMRI data, and explores the application of deep learning within the medical domain. The key
207 contributions of this study are outlined as follows.

- 208 • Utilizing 3D CNN while preserving the image's spatial information.
- 209 • The 3DMRIwHR fusion method for combining neuroimages and textual data results in
210 reduced algorithm complexity and time requirements.
- 211 • Make use of information between layers for early detection of AD using 3D sMRI
212 processing
- 213 • Comparative analysis of classification performance between the 3D and 2D CNN models.
- 214 • Enhanced early and late MCI diagnosis through the inclusion of HR for both 3D and 2D
215 sMRI classification.

216

217 **Material and methods**

218 **Data collection**

219 The data employed in this study were derived from the ADNI dataset. Initiated in October 2004
220 under the guidance of Dr. Michael W. Weiner, the ADNI dataset comprises clinical, biochemical,
221 and genetic biomarkers, along with neuroimaging modalities such as MRI and PET. These
222 resources can be used for early diagnosis, prevention, and treatment of AD. The study encompassed
223 the initial six years of the ADNI project, denoted as ADNI 1. Subsequent phases include ADNI
224 GO (2009-2011), ADNI 2 (2011-2016), and the ongoing ADNI 3 (2016 to the present). Throughout
225 these stages, image protocols were refined, new participants were incorporated, and diverse data
226 types were integrated into the project.

227 In this study, a cohort of 780 participants was examined, comprising 178 AD patients, 176 patients
228 with EMCI, 161 patients with LMCI, and 265 CN patients. The 3D sMRI scans were acquired in
229 T1-weighted format, with an in-plane spatial size of $1.25 \times 1.25 \text{ mm}^2$ and a thickness of 1.2 mm in
230 3D MPRAGE format. In addition to neuroimaging data, the study encompassed demographics,
231 cognitive metrics, and genetic information of the participants. Patient health records, encompassing
232 demographic factors like age and gender, ApoE- ϵ 4 genetic data, and MMSE cognitive measure
233 data were fused with 3D sMRI data. Consequently, a 3D CNN model based on 3DMRIwHR images
234 was deployed to classify the four distinct cognitive states associated with dementia: normal
235 cognition, early mild cognitive impairment, late mild cognitive impairment, and AD. Table 1
236 provides details about the participant count and other pertinent information for each group. The
237 majority of participants were over 65 years old, with MMSE scores exceeding 19, and a greater
238 prevalence of negative ApoE- ϵ 4 values compared to positive ones.

239 **Table 1. Demographic, Cognitive Score and Gene Data of All Subjects**

Data	Values	CN	EMCI	LMCI	AD	Total
age	<u>56-65</u>	5	19	23	12	<u>59</u>
	<u>66-75</u>	87	89	57	56	<u>289</u>
	<u>76-85</u>	122	60	69	81	<u>332</u>
	<u>86-95</u>	51	8	12	29	<u>100</u>
gender	<u>female</u>	138	77	75	75	<u>365</u>
	<u>male</u>	127	99	86	103	<u>415</u>
MMSE	<u>0-9</u>	0	0	0	0	<u>0</u>
	<u>10-18</u>	0	0	0	10	<u>10</u>
	<u>19-24</u>	2	3	33	112	<u>150</u>
	<u>25-30</u>	263	173	128	56	<u>620</u>
ApoE ϵ4	<u>positive</u>	74	75	90	46	<u>285</u>
	<u>negative</u>	191	101	71	132	<u>495</u>

AD: Alzheimer's Disease

CN: Cognitively Normal

EMCI: Early Mild Cognitive Impairment

240

241 **Preprocessing**

242 Taking computational efficiency into consideration, the initial step involved preprocessing the
243 images through the utilization of FMRIB Software Library v6.0.5.2. The 3D sMRI data, initially
244 registered using FMRIB's Linear Image Registration Tool module, underwent bias field correction
245 using the FLIRT module. This procedure eliminated the density gradient that could impact the
246 segmentation algorithm. MRI measurements pertaining to the skull, skin, fat, muscle, neck, and
247 eyeballs were deemed insignificant for disease identification. A brain extraction tool module was
248 applied to remove non-brain tissues, including the skull. Subsequently, intensity normalization was
249 executed to rectify density variations potentially arising due to differing image sizes. The final
250 preprocessing stage involved resizing the 3D images from $176 \times 240 \times 256$ to $50 \times 30 \times 20$, a
251 resolution validated in [20]. The adoption of larger image sizes would result in heightened
252 computational complexity, rendering them unfeasible for implementation on conventional
253 computers.

254 To compare the impact of fusing health records with MRI scans for multi-class image
255 classification, both 2D and 3D image data fusion methodologies were employed. From the
256 preprocessed and unresized 3D images, 2D slices were extracted after skull-stripping. In the final
257 phase of 2D MRI preprocessing, these slices were saved in PNG format with 256×256 pixels.

258 Within the ADNI dataset, subjects with health records encompassing age, gender, ApoE- ϵ 4, and
259 MMSE are limited and are imbalanced across AD, LMCI, EMCI, and CN categories. Following a

260 20% allocation for testing, data augmentation was undertaken to increase the dataset's size for both
261 the 2D and 3D CNN models. The number of images per class, initially set at 1000, was doubled
262 through this process. Consequently, the shuffled dataset, encompassing 8000 MRI scans, was
263 subsequently partitioned into two sets: training and validation.


264 **Fusing 3D sMRI with Health Records: 3DMRIwHR Method**

265 In the diagnosis of Alzheimer's disease, a specialist physician conducts a range of examinations
266 after reviewing the patient's medical history. These examinations encompass neuropsychological,
267 neurophysiological, genetic, laboratory, neuroimaging, and nuclear medicine tests. Disease
268 diagnosis isn't solely reliant on neuroimaging; it also involves the analysis of diverse data types.
269 Healthcare professionals face restricted opportunities to effectively utilize these varied data forms.
270 Despite the growing body of research on this subject, MRI remains the preferred approach. In this
271 study, we introduced a method named 3DMRIwHR, which facilitates the assessment of
272 neuroimaging data by combining demographic, genetic, and cognitive test score outcomes. When
273 selecting test results represented by 3D-HR markers, factors that heightened the risk of AD
274 symptoms were considered.

275 3D sMRI contains additional information between layers, a feature not present in 2D sMRI.
276 However, extracting this information through visual inspection of 3D sMRI images is not trivial.
277 Machine learning techniques, however, can effectively harness this information. To underscore the
278 interdimensional impact of the 3D method, a fusion procedure was applied to 2D slices derived
279 from 3D images within the proposed deep learning model. This approach, utilizing the same data,
280 is designated as 2DMRIwHR.

281 The approach used in the study encompassed the fusion of text-based information with sMRI scans
282 through the utilization of 3D volumetric pipe-shaped markers. In marker design, preference was

283 given to half and full rectangular prism shapes in black or white, with each color symbolizing
284 specific attributes. These textual attributes included age, gender, ApoE-ε4 gene value, and MMSE
285 score ranges. Figure 1 illustrates the attribute values associated with these colored volumetric pipes.
286 The characteristics of the markers utilized in the fusion of 2D images, along with their
287 corresponding value ranges and arrangement on the image, were applied similarly to the
288 3DMRIwHR method, with no changes except for spatial criteria. Upon extracting the 2D images
289 as detailed in the data preprocessing section, they were combined with 2D markers that represented
290 textual information. This methodology was labeled as 2DMRIwHR. Following this technique's
291 application, training was done on the proposed 2D model without including any additional image
292 enhancements



293


294 **Figure 1. 3D pipe shape coding for health records**

295 In this study, four distinct health records — age, gender, MMSE, and ApoE-ε4 gene data — were
296 utilized to construct 3D-HR pipes, as shown in Figure 1. Each of the 3D pipes created using the
297 3DMRIwHR method had a height of eight pixels, a width of 20 pixels, and a depth of 256 pixels.

298 The processing involved 3D images in NIfTI format, with dimensions of $176 \times 240 \times 256$, carried
299 out in the axial plane, spanning from pixel points (2, 10) to (10,49). Gaps of size (5×4) were
300 deliberately left between the pipe markers to ensure that volumetric markers did not generate any
301 erroneous correlations. 3D-HR pipes were located in the corners of the 3D sMRI scans for the

302 purpose of data fusion. The corner's selection was such that it didn't impede the 3D brain image. In
303 the case of the 2DMRIwHR method, 2D planar markers, with dimensions of eight pixels in height
304 and 20 pixels in width, were employed. The positioning process on the image closely resembled
305 that of the 3DMRIwHR method.

306 To visualize the Nifti scans, the 3D axial preprocessed and 3DMRIwHR images were transformed
307 into PNG files, as shown in Figure 2. The 3D-HR pipes representing age, gender, ApoE-ε4, and
308 MMSE scores on the image were placed in a specific order.



309

310 **Figure 2. 3D MRI with and without 3D-HR pipes**

311 2D MRI images were extracted from the 3D sMRI images by means of slicing. After the slicing
312 phase, the 2D images in Nifti format were combined with health records using 2D encoding. The
313 markers employed in the 2D images denoted the same values as those in the 3D-HR pipes. While
314 the alignment of marker images remained consistent, due to the 2D and planar nature of the images,
315 the 2D markers were depicted as rectangles, measuring eight pixels in height and 20 pixels in width.

316

317

318

319 **Classification for Decision Support**

320 CNNs are a specific type of neural network designed for processing data organized in matrix form.
321 Convolutional networks have proven effective in real-world applications, yielding satisfactory
322 outcomes not only with large datasets but also when adeptly modeled for smaller datasets. In the
323 realm of image processing studies [19,20,22], the architecture of CNN best fits the concept of
324 learning regional patterns by transforming pixel data into matrices. Given that dementia impacts
325 specific brain regions, we employed 2D and 3D CNN architectures to classify the four classes,
326 namely CN, EMCI, LMCI, and AD.

327


328 **3D CNN method**

329 The proposed model comprises three 3D convolutional layers and three 3D max pools. Following
330 these layers, a dropout layer was introduced, succeeded by a flattened layer. At the model's last
331 layer, there existed an FC layer employing a softmax activation function. The 3D convolutional
332 layers were all equipped with $3 \times 3 \times 3$ kernels and $1 \times 1 \times 1$ stride values, featuring 64 filters in
333 the initial two convolutional layers and 128 filters in the final layer. The pooling layer kernels were
334 all of size $3 \times 3 \times 3$, with stride values set at $2 \times 2 \times 2$. The number of training parameters was
335 1,710,660, whereas the number of non-trainable parameters was 0. For optimization during
336 parameter training, the adaptive moment-estimation (ADAM) optimization algorithm was utilized
337 with a learning rate of 0.001.

338 Since the rectified linear unit (RELU) is currently the most commonly applied function [21], it was
339 used as the activation function in the three convolutional layers. A dropout value of 0.5 was selected
340 to mitigate the risk of overfitting. Following the softmax activation function in the final FC layer,

341 a 4-class disease classification was executed. The architectural layout of the 3D CNN model can
342 be observed in Figure 3.

343



344

345 **Figure 3. 3D CNN Model Architecture**

346

347 **2D CNN Method**

348 In the 2D CNN model, there were three 2D convolutional layers accompanied by three 2D max
349 pools. These were followed by a dropout layer, succeeded by a flattened layer. The model's
350 conclusion included an FC layer employing a softmax activation function. The 2D convolutional
351 layers all consisted of 3×3 kernels with 1×1 stride values, with 64 filters present in the initial
352 two convolutional layers and 128 in the last convolutional layer. The pooling layer kernels were
353 all 3×3 in size, with stride values set at 2×2 . The number of training parameters was 16,889,284,
354 whereas the number of non-trainable parameters was 0. An optimization algorithm, specifically
355 "ADAM" was utilized with a learning rate of 0.001 during parameter training.

356 As for the activation function, RELU was utilized for the three convolutional layers due to its
357 widespread application [21]. A dropout value of 0.5 was selected to counteract overfitting. The

358 classification of the four dementia groups was carried out based on the softmax activation function
359 in the final FC layer.

360

361 **Experimental Design**

362 In our study, the proposed models considered the impact of health records on classifier
363 performance. To illustrate the effect of health records on recognition rates, the comparison was
364 made between 2D MR vs. 2DMRIwHR and 3D MR vs. 3DMRIwHR, utilizing 2D CNN and 3D
365 CNN deep-learning techniques, respectively.

366 The 2D and 3D classification methods were implemented using the Keras 2.8.0 library in Python
367 3.9, built on TensorFlow-gpu 2.8.0. The execution occurred on a PC equipped with an NVIDIA
368 RTX2060 GPU running the Windows operating system. In the network, the Adaptive Moment
369 Estimation (ADAM) optimizer was employed, starting with an initial learning rate of 0.001. A
370 dropout rate of 0.5 was set to mitigate overfitting. For 3D classification, the batch size was set to
371 64, while the 2D classification employed a batch size of 128.

372 The image count for each class was divided into two sets using a 0.8 training and 0.2 testing ratio.
373 Subsequently, data augmentation was applied to the train set, effectively doubling the number of
374 images in each class. As a result, the overall training dataset containing 8000 images was divided
375 into a training set (comprising 64% of the images), a validation set (consisting of 16% of the
376 images). During the classification phase, only images belonging to the class with the lowest image
377 count were utilized to accurately assess the impact of the pipe-laying process. This approach
378 ensured balanced representation among classes.

379

380

381 **Data Augmentation**

382 The image count for each class was divided into two sets using a 0.8 training and 0.2 testing ratio.
383 Subsequently, data augmentation was applied to the train set, effectively doubling the number of
384 images in each class. As a result, the overall training dataset containing 8000 images was divided
385 into a training set (comprising 64% of the images), a validation set (consisting of 16% of the
386 images).


387 The 2D and 3D classification methods were implemented using the Keras 2.8.0 library in Python
388 3.9, built on TensorFlow-gpu 2.8.0. The execution occurred on a PC equipped with an NVIDIA
389 RTX2060 GPU running the Windows operating system. In the network, the Adaptive Moment
390 Estimation (ADAM) optimizer was employed, starting with an initial learning rate of 0.001. A
391 dropout rate of 0.5 was set to mitigate overfitting. For 3D classification, the batch size was set to
392 64, while the 2D classification employed a batch size of 128.

393

394 **Results and Discussion**

395 The 3D CNN method using only MRI achieved an accuracy of 86.87%, while the inclusion of
396 health records (3DMRIwHR) improved accuracy by 3.13% for multi-class classification of
397 preprocessed medical images involving AD, LMCI, EMCI, and CN categories. Similarly, the 2D
398 CNN method without health records achieved an accuracy of 81.43%, which increased to 87.00%
399 when health records were integrated. Given the improved performance of both 2D and 3D CNN
400 models with health records, it can be inferred that combining health records with MRI data leads
401 to superior outcomes. Furthermore, it was observed that the 3D CNN model with health records
402 outperformed the 2D CNN model with health records due to its ability to leverage spatial
403 information between the 2D layers of MRI. As depicted in Figures 4 and 5, the training and


404 validation accuracies provide evidence that the proposed models function effectively without
405 overfitting.



406

407 **Figure 4. Training and validation accuracy and loss for 3D classification model**

408



409


410 **Figure 5. Training and validation accuracy and loss for 2D classification model (a) with and (b) without 3D-HR data**

411

412 Evidently, the 3D CNN model surpassed the 2D CNN model in classifying both pre- and post-
413 method datasets. The utilization of information across layers in 3D sMRI scans, as opposed to 2D
414 images, grants the 3D CNN model a greater classification advantage. Illustrated in Figures 4 and
415 5, the difference in accuracy rates before and after applying the method was less pronounced in 3D

416 classification compared to 2D classification, mainly due to the richer features present in 3D images.
417 Notably, the additional features introduced alongside health records exhibited a more substantial
418 impact on the classification accuracy of pre- and post-method 2D images, despite their lower
419 overall feature count.
420 The confusion matrix illustrates the performance of the proposed 3D classifier in distinguishing
421 various class labels when the 3DMRIwHR method is not utilized, as depicted in Figure 6. Without
422 the application of the 3DMRIwHR method, 691 out of 800 images were accurately predicted, while
423 109 were predicted incorrectly. In the post-method classification, 720 out of 800 images were
424 correctly predicted, and 80 were inaccurately predicted. By ranking disease stages by severity as
425 AD, LMCI, EMCI, and CN, the error matrix revealed that the detection capability improved with
426 the 3DMRIwHR method as the disease progressed to more severe stages.

427




428

429 **Figure 6. The confusion matrix for preprocessed and pipe layed data 3D classification model**

430

431 The confusion matrix shows the effectiveness of the proposed 2D classifier in categorizing
432 different class labels when the 2DMRIwHR method is both applied and not applied, as shown in

433 Figure 7. In cases where the 2DMRIwHR method was not used, 645 of the 800 images were
434 accurately predicted, while 155 were incorrectly predicted. Following the post-method
435 classification, 698 out of 800 images were correctly predicted, and 102 were predicted inaccurately.
436 Similar to the 3D classifier, a pattern emerged in the confusion matrix for the 2D classifier,
437 indicating improved detection ability with the 2DMRIwHR method as the disease severity
438 escalated.
439



440

441 **Figure 7. The confusion matrix for preprocessed and pipe layed data 2D classification model**

442

443 Comparing results before and after the application of the 3DMRIwHR method in the order of class
444 levels CN, EMCI, LMCI, and AD revealed an increase in the predictive capability of the proposed
445 model with rising disease levels. Notably, the 3D CNN model accurately identified all images in
446 the AD class, regardless of the presence of this method. The highest estimation for the healthy class
447 (CN) was achieved when the 3DMRIwHR method was applied, utilizing a single MMSE 3D-HR
448 marker. Within the EMCI class, the highest estimation occurred in the classification following the
449 3DMRIwHR method, wherein all markers were applied collectively. The proposed method notably

450 heightened predictive accuracy for the early MCI level, which signifies the disease's initial stage
451 and aligns with the study's goal of early diagnosis.

452 Regarding the LMCI class, the method's application using a single age 3D-HR marker resulted in
453 the highest predictive accuracy. The decreased classification accuracy observed when combining
454 images with ApoE ϵ 4 3D-PI markers, compared to the rate without the method, can be attributed
455 to the dataset's composition: 285 participants exhibited positive values, while 495 displayed
456 negative values.

457 The evaluation of the model encompassed the analysis of accuracy, loss, confusion metrics, F1
458 score, recall, and precision parameters. Table 2 presents the performance metrics of the model after
459 100 learning epochs.

460

461

462

463 **Table 1. Comparison of the Performance Metrics of 3D CNN Model with and without 3DMRIwHR**

	3D MRI			3DMRIwHR			
	Precision	Recall	F ₁ -Score	Precision	Recall	F ₁ -Score	Support
AD	0.97	1.00	0.98	1.00 (+0.03)	1.00	1.00 (+0.02)	200
LMCI	0.81	0.85	0.83	0.85 (+0.04)	0.92 (+0.7)	0.88 (+0.05)	200
EMCI	0.86	0.74	0.80	0.82 (-0.04)	0.90 (+0.16)	0.86 (+0.04)	200
CN	0.82	0.86	0.84	0.95 (+0.13)	0.79 (-0.7)	0.86 (+0.02)	200
Avg	0.86	0.86	0.86	0.91 (+0.05)	0.90 (+0.04)	0.90 (+0.04)	800

464

465 The precision column displays values signifying the actual criteria for accurately classified images
466 among all samples categorized as positive. Without utilizing this method, the precision criterion
467 for correctly classifying patients with AD was 0.97. With the implementation of this method, this

468 ratio improved to 1.00. Notably, precision values exhibit a progressive increase in accordance with
469 the proposed method as patient groups are arranged from worse to better.

470 The second column presents the sensitivity (recall) scale, which signifies the model's capability to
471 detect positive samples. For the patients with EMCI, the sensitivity rate elevated from 0.74 to 0.90.
472 Application of the 3DMRIwHR method led to increased sensitivity rates in diagnosing patient
473 groups but decreased rates in the healthy group.

474 The F1 score, a harmonic mean of precision and sensitivity values, was chosen to avoid incorrect
475 model selection in unbalanced datasets. Given the study's use of balanced datasets, the F1 score
476 closely mirrored the precision values in the research outcomes. Noticeably, these values escalated
477 for all classes, with no imbalance between precision and sensitivity. While F1 scores did not
478 decrease for cases before and after applying the method, enhancements were evident in the AD,
479 LMCI, and CN classes.

480 For the 2D CNN performance metrics, Table 3 details precision, sensitivity, and F1 scores for each
481 class in scenarios with and without the proposed method. Prior to employing the 2DMRIwHR
482 method, the precision criterion for AH images was 0.78, which increased to 0.86 with the method.
483 The sensitivity also grew by 0.10 for patients with EMCI. F1 scoring values witnessed elevation
484 for all classes and there was no imbalance between the precision and sensitivity values. In post-
485 method classification, all metrics in the model exhibited improvement, barring the sensitivity value
486 for the CN class.

487

488

489

490 **Table 2. Comparison of the Performance Metrics of 2D CNN with and without 2DMRIwHR**

	<i>2D MRI</i>			<i>2D MRIwHR</i>			
	Precision	Recall	F ₁ -Score	Precision	Recall	F ₁ -Score	Support
<i>AD</i>	0.78	0.92	0.84	0.86 (+0.08)	0.94 (+0.06)	0.90 (+0.06)	200
<i>LMCI</i>	0.83	0.76	0.79	0.84 (+0.01)	0.92 (+0.16)	0.88 (+0.09)	200
<i>EMCI</i>	0.82	0.82	0.82	0.86 (+0.04)	0.92 (+0.1)	0.89 (+0.07)	200
<i>CN</i>	0.80	0.72	0.76	0.93 (+0.13)	0.69 (-0.03)	0.79 (+0.03)	200
<i>Avg</i>	0.81	0.81	0.80	0.87 (+0.06)	0.87 (+0.06)	0.86 (+0.06)	800

491

492 Separate processes were conducted on both 2D and 3D images to assess the impact of the data
493 fusion method across dimensions. Based on performance metrics, classification outcomes for 3D-
494 HR data were consistently superior to those achieved without 3D-HR data in both models.
495 Moreover, our study affirmed that a 3D CNN outperformed a 2D CNN in MRI classification
496 accuracy. Similarly, akin to the 3D fusion method, patient health records were incorporated with
497 2D MRI images. However, extracting meaningful information from 3D sMRI visually is a
498 nontrivial task. It has been evidenced that deep learning techniques applied to 3D sMRI, leveraging
499 inter-layer information, yielded enhanced recognition results compared to other techniques
500 employing 2D sMRI.

501 This data fusion study encompasses several factors contributing to its uniqueness, such as
502 preprocessing and 3D-HR encoding, simultaneous utilization of neuroimages and health records,
503 and harnessing the 3D CNN architecture to achieve elevated accuracy through learning regional
504 patterns, distinguishing it from prior studies. To highlight the impact of the fusion method, results
505 both with and without the fusion method are presented. We trained markers as features,
506 transforming them into features during the preprocessing stage, thereby avoiding separate training
507 and reducing computational time.

508 **Conclusion**

509 Computer-aided systems have the potential to aid doctors in achieving faster and more precise
510 diagnoses during the early stages of AD. To achieve this goal, data beyond patient images is
511 employed within the diagnostic process. Consequently, the types of data utilized can be diverse.
512 CAD systems can experience enhancements when incorporating various data types. In our study,
513 alongside image data, demographic information like age, gender, MMSE, and ApoE- ϵ 4 was
514 integrated.

515 In this study, classification was performed using a CNN architecture based on fused sMRI data,
516 with textual health records coded as image markers to detect AD. Data fusion was performed on
517 the preprocessed MRI by transforming participant attributes such as demographic features like age,
518 gender, ApoE- ϵ 4 gene information, and MMSE cognitive scores into image markers. In multi-class
519 classification, accuracy values were obtained for the 2D and 3D CNN. The test results
520 demonstrated that fusing health records increased the recognition rates for Alzheimer's diagnosis.

521 Our study revealed that different types of data can be used to detect AD. Adding health records to
522 MRI scans increases the AD diagnosis recognition rates. The accuracy of 3DMRIwHR is better
523 than that of 2DMRIwHR because the 3D image architecture exploits the spatial information
524 between 2D slices in sMRI. However, the 2D CNN classification method produces a better
525 accuracy than the 2D LSTM-based RNN because of its pattern detection approach. The
526 3DMRIwHR method achieved a high recognition accuracy with multi-class dementia evolution.
527 Thus, practitioners can gain better insights by observing the early phases of dementia diagnosis
528 based on multiple features.

529 Reducing examination time and facilitating diagnoses through CAD systems can expedite the
530 dementia diagnosis process for healthcare professionals. Our study demonstrates that diverse data

531 formats can be combined to achieve enhanced accuracy rates while maintaining lower
532 computational complexity. This empowers doctors and specialists to diagnose dementia by
533 utilizing all available patient-related data.

534 In conclusion, our study proposes that the 3D data fusion approach can serve not only for
535 classification but also for predicting convertible MCI.

536

537 **Additional Information and Declarations**

538 **Funding**

539 This research was not funded by any initiative, including the Alzheimer’s Disease Neuroimaging
540 Initiative.

541

542 **Competing Interests**

543 The authors declare that they have no competing interests.

544

545 **Author Contributions**

546 ▪ Arman Atalar conceived and designed the experiments, performed the experiments, analyzed
547 the data, prepared figures and/or tables, authored or reviewed drafts of the paper, performed
548 the computation work, and approved the final draft.

549 ▪ Savas Okyay conceived and designed the experiments, analyzed the data, authored or reviewed
550 drafts of the paper, and approved the final draft.

551 ▪ Nihat Adar conceived and designed the experiments, analyzed the data, authored or reviewed
552 drafts of the paper, and approved the final draft.

553

554 **Acknowledgements**

555 We thank neurologist Dr. Serdar Eren (LÖSANTE) for providing us with information about the
556 clinical procedures.

557

558 **Human Ethics**

559 The following information was supplied relating to ethical approvals (i.e., approving body and any
560 reference numbers):

561 Alzheimer’s Disease Neuroimaging Initiative: “All ADNI data are shared without embargo through
562 the LONI Image and Data Archive (IDA), a secure research data repository. Interested scientists
563 may obtain access to ADNI imaging, clinical, genomic, and biomarker data for the purposes of
564 scientific investigation, teaching, or planning clinical research studies. Access is contingent on
565 adherence to the ADNI Data Use Agreement and the publications’ policies outlined in the
566 documents listed below. Note: documents are subject to updates by ADNI.” More information is
567 available at <https://adni.loni.usc.edu/data-samples/access-data/>.

568

569 **Data Availability**

570 The following information was supplied regarding data availability:

571 The project repository containing the supplementary material and other sources are available at
572 GitHub: <https://github.com/armanatatar/3DMRIwHR>.

573 The data is available at <http://adni.loni.usc.edu/data-samples/access-data/>.

574 Data collection and sharing for this project was provided by the Alzheimer’s Disease
575 Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD
576 ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the
577 National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and

578 through generous contributions from the following: AbbVie, Alzheimer’s Association;
579 Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-
580 Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly
581 and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech,
582 Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research &
583 Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.;
584 Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research;
585 Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging;
586 Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes
587 of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector
588 contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).
589 The grantee organization is the Northern California Institute for Research and Education, and the
590 study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of
591 Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the
592 University of Southern California.

593

594 **References**

- 595 1. WHO. Public health response to dementia [Internet]. Geneva: World Health Organization.
596 2021. 137 p. Available from: <https://www.who.int/publications/i/item/9789240033245>
- 597 2. Sudre CH, Cardoso MJ, Modat M, Ourselin S. Imaging biomarkers in Alzheimer’s disease.
598 In: Handbook of Medical Image Computing and Computer Assisted Intervention [Internet].
599 Elsevier; 2020. p. 343–78. Available from:

- 600 <https://linkinghub.elsevier.com/retrieve/pii/B978012816176000020X>
- 601 3. Lin SY, Lin PC, Lin YC, Lee YJ, Wang CY, Peng SW, et al. The Clinical Course of Early
602 and Late Mild Cognitive Impairment. *Front Neurol.* 2022;13(May):1–10.
- 603 4. Atalar A. Early detection of alzheimer’s disease with deep learning using 3d MRI and patient
604 informations. 2022;
- 605 5. Yang J, Feng X, Laine AF, Angelini ED. Characterizing Alzheimer’s Disease with Image
606 and Genetic Biomarkers Using Supervised Topic Models. *IEEE J Biomed Heal Informatics.*
607 2020;24(4):1180–7.
- 608 6. Okyay S, Adar N. Dementia-related user-based collaborative filtering for imputing missing
609 data and generating a reliability scale on clinical test scores. *PeerJ.* 2022;10:1–19.
- 610 7. Liu M, Zhang J, Adeli E, Shen Di. Joint classification and regression via deep multi-task
611 multi-channel learning for Alzheimer’s disease diagnosis. *IEEE Trans Biomed Eng.*
612 2019;66(5):1195–206.
- 613 8. Pillai PS, Leong TY. Fusing Heterogeneous Data for Alzheimer’s Disease Classification.
614 *Stud Health Technol Inform.* 2015;216:731–5.
- 615 9. Kaur J, Shekhar C. Multimodal medical image fusion using deep learning. In: *Advances in*
616 *Computational Techniques for Biomedical Image Analysis [Internet]. Elsevier; 2020. p. 35–*
617 *56. Available from: <https://linkinghub.elsevier.com/retrieve/pii/B9780128200247000025>*
- 618 10. Sørensen L, Nielsen M. Ensemble support vector machine classification of dementia using
619 structural MRI and mini-mental state examination. *J Neurosci Methods [Internet].* 2018
620 May;302:66–74. Available from:

- 621 <https://linkinghub.elsevier.com/retrieve/pii/S0165027018300177>
- 622 11. Forouzannezhad P, Abbaspour A, Li C, Cabrerizo M, Adjouadi M. A Deep Neural Network
623 Approach for Early Diagnosis of Mild Cognitive Impairment Using Multiple Features. Proc
624 - 17th IEEE Int Conf Mach Learn Appl ICMLA 2018. 2018;1341–6.
- 625 12. Liu S, Liu S, Cai W, Che H, Pujol S, Kikinis R, et al. Multimodal Neuroimaging Feature
626 Learning for Multiclass Diagnosis of Alzheimer’s Disease. IEEE Trans Biomed Eng.
627 2015;62(4):1132–40.
- 628 13. Punjabi A, Martersteck A, Wang Y, Parrish TB, Katsaggelos AK. Neuroimaging modality
629 fusion in Alzheimer’s classification using convolutional neural networks. PLoS One
630 [Internet]. 2019;14(12):1–14. Available from:
631 <http://dx.doi.org/10.1371/journal.pone.0225759>
- 632 14. Zhang Y, Wang S, Xia K, Jiang Y, Qian P. Alzheimer’s disease multiclass diagnosis via
633 multimodal neuroimaging embedding feature selection and fusion. Inf Fusion [Internet].
634 2021 Feb;66:170–83. Available from:
635 <https://linkinghub.elsevier.com/retrieve/pii/S1566253520303638>
- 636 15. Lin W, Gao Q, Du M, Chen W, Tong T. Multiclass diagnosis of stages of Alzheimer’s
637 disease using linear discriminant analysis scoring for multimodal data. Comput Biol Med
638 [Internet]. 2021 Jul;134:104478. Available from:
639 <https://linkinghub.elsevier.com/retrieve/pii/S0010482521002729>
- 640 16. Pelka O, Friedrich CM, Nensa F, Mönninghoff C, Bloch L, Jöckel KH, et al.
641 Sociodemographic data and APOE-ε4 augmentation for MRI-based detection of amnesic
642 mild cognitive impairment using deep learning systems. PLoS One. 2020;15(9)

643 September):1–24.

644 17. Payan A, Montana G. Predicting Alzheimer’s disease a neuroimaging study with 3D
645 convolutional neural networks. ICPRAM 2015 - 4th Int Conf Pattern Recognit Appl
646 Methods, Proc. 2015;2:355–62.

647 18. Hosseini-Asl E, Keynton R, El-Baz A. Alzheimer’s disease diagnostics by adaptation of 3D
648 convolutional network. Proc - Int Conf Image Process ICIP. 2016;2016-Augus(502):126–
649 30.

650 19. Sahumbaiev I, Popov A, Ramírez J, Górriz JM, Ortiz A. 3D-CNN HadNet classification of
651 MRI for Alzheimer’s Disease diagnosis. 2018 IEEE Nucl Sci Symp Med Imaging Conf
652 NSS/MIC 2018 - Proc. 2018;3–6.

653 20. Helaly HA, Badawy M, Haikal AY. Deep Learning Approach for Early Detection of
654 Alzheimer’s Disease. Cognit Comput [Internet]. 2022;14(5):1711–27. Available from:
655 <https://doi.org/10.1007/s12559-021-09946-2>

656 21. Jayanthi VS, Simon BC, Baskar D. Alzheimer’s disease classification using deep learning.
657 In: Computational Intelligence and Its Applications in Healthcare [Internet]. Elsevier;
658 2020. p. 157–73. Available from:
659 <https://linkinghub.elsevier.com/retrieve/pii/B978012820604100011X>

660

661